Impact of Apolipoprotein B on Hepatosteatosis in a Population Infected with Hepatitis C Virus: A Cross-Sectional Observational Study

• Published in: Obesity facts Vol. 9; no. 2; pp. 101 - 111
• Main Authors: Lin, Ming-Shyan, Guo, Su-Er, Lin, Huang-Shen, Hsu, Jen-Te, Lin, Yu-Sheng, Lin, Tsai-Hui, Huang, Tung-Jung, Chen, Mei-Yen, Chung, Chang-Min
• Format: Journal Article
• Language: English
• Published: Basel, Switzerland S. Karger GmbH 01.01.2016; Karger Publishers
• Subjects: Adult; Aged; Apolipoprotein B-100 - blood; Apolipoprotein-B; Cross-Sectional Studies; Female; Hepacivirus; Hepatitis C virus; Hepatitis C, Chronic - blood; Hepatitis C, Chronic - virology; Humans; Incidence; Logistic Models; Male; Middle Aged; Non-alcoholic fatty liver disease; Non-alcoholic Fatty Liver Disease - blood; Non-alcoholic Fatty Liver Disease - diagnostic imaging; Non-alcoholic Fatty Liver Disease - virology; Original; Original Article; Prevalence; Risk Factors; Taiwan; Ultrasonography; Hepatitis C virus; Non-alcoholic fatty liver disease; Apolipoprotein-B
• ISSN: 1662-4025; 1662-4033; 1662-4033
• DOI: 10.1159/000443692

Objective: Non-alcoholic fatty liver disease (NAFLD) is an established risk factor for diabetes, cardiovascular disease, antiviral treatment resistance, and progression of chronic hepatitis C virus (HCV) infection to fibrosis. Apolipoprotein-B 100 (ApoB-100) is a dyslipidemia marker and steatosis predictor. We assess the correlation between ApoB-100 and hepatosteatosis. Methods: This cross-sectional study enrolled 1,218 HCV-seropositive participants from a 2012-2013 health checkup in Taiwan. NAFLD was detected using ultrasound. All anthropometric and laboratory studies that included ApoB-100 were evaluated whether or not ApoB-100 predicts NAFLD. Logistic regression was also used to examine the association between ApoB-100 and NAFLD. Results: Participants were 47.16 ± 16.08 years old (mean age). The overall prevalence of NAFLD was 35.8% (n = 436; 32.8% men, 38.1% women). Participants with ApoB-100 ≥ 8 had a significantly higher incidence of NAFLD (39.4 vs. 29.4%; 95% CI 0.044-0.156; p < 0.001). After confounding factors had been adjusted for, ApoB-100 was significantly associated with NAFLD (OR 5.45; 95% CI 1.64-18.06; p = 0.006) and high-grade hepatosteatosis (OR 7.73; 95% CI 1.74-34.35; p = 0.007). Conclusion: ApoB-100 is strongly associated with NAFLD in people with non-genotype 3 HCV; greater ApoB-100 content is significantly correlated with higher-grade hepatosteatosis.